New antibody combo targets leukemia stem cells in early trial
NCT ID NCT06548230
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 26 times
Summary
This early-phase trial tests a new drug called nadunolimab combined with standard treatments (azacitidine, with or without venetoclax) in 40 people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The goal is to see if the combination is safe and to find the best dose. The study targets leukemia stem cells, which are hard to kill and can cause the cancer to return.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME (MDS) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.